التفاصيل البيبلوغرافية
| العنوان: |
First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK |
| المؤلفون: |
Silvano Gnesin, Periklis Mitsakis, Francesco Cicone, Emmanuel Deshayes, Vincent Dunet, Augusto F. Gallino, Marek Kosinski, Sébastien Baechler, Franz Buchegger, David Viertl, John O. Prior |
| المصدر: |
EJNMMI Research, Vol 7, Iss 1, Pp 1-10 (2017) |
| بيانات النشر: |
SpringerOpen, 2017. |
| سنة النشر: |
2017 |
| المجموعة: |
LCC:Medical physics. Medical radiology. Nuclear medicine |
| مصطلحات موضوعية: |
Angiogenesis, Dosimetry, PET/CT, 68Ga-NODAGA-RGDyK, Choroid plexuses, Integrin αvβ3, Medical physics. Medical radiology. Nuclear medicine, R895-920 |
| الوصف: |
Abstract Background Integrin-targeting radiopharmaceuticals have potential broad applications, spanning from cancer theranostics to cardiovascular diseases. We have previously reported preclinical dosimetry results of 68Ga-NODAGA-RGDyK in mice. This study presents the first human dosimetry of 68Ga-NODAGA-RGDyK in the five consecutive patients included in a clinical imaging protocol of carotid atherosclerotic plaques. Five male patients underwent whole-body time-of-flight (TOF) PET/CT scans 10, 60 and 120 min after tracer injection (200 MBq). Quantification of 68Ga activity concentration was first validated by a phantom study. To be used as input in OLINDA/EXM, time-activity curves were derived from manually drawn regions of interest over the following organs: brain, thyroid, lungs, heart, liver, spleen, stomach, kidneys, red marrow, pancreas, small intestine, colon, urinary bladder and whole body. A separate dosimetric analysis was performed for the choroid plexuses. Female dosimetry was extrapolated from male data. Effective doses (EDs) were estimated according to both ICRP60 and ICRP103 assuming 30-min and 1-h voiding cycles. Results The body regions receiving the highest dose were urinary bladder, kidneys and choroid plexuses. For a 30-min voiding cycle, the EDs were 15.7 and 16.5 μSv/MBq according to ICRP60 and ICRP103, respectively. The extrapolation to female dosimetry resulted in organ absorbed doses 17% higher than those of male patients, on average. The 1-h voiding cycle extrapolation resulted in EDs of 19.3 and 19.8 μSv/MBq according to ICRP60 and ICRP103, respectively. A comparison is made with previous mouse dosimetry and with other human studies employing different RGD-based radiopharmaceuticals. Conclusions According to ICRP60/ICRP103 recommendations, an injection of 200 MBq 68Ga-NODAGA-RGDyK leads to an ED in man of 3.86/3.92 mSv. For future therapeutic applications, specific attention should be directed to delivered dose to kidneys and potentially also to the choroid plexuses. Trial registration Clinical trial.gov, NCT01608516 |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2191-219X |
| Relation: |
http://link.springer.com/article/10.1186/s13550-017-0288-x; https://doaj.org/toc/2191-219X |
| DOI: |
10.1186/s13550-017-0288-x |
| URL الوصول: |
https://doaj.org/article/57fdd9a8d4644ce6a32447c324ae07bb |
| رقم الانضمام: |
edsdoj.57fdd9a8d4644ce6a32447c324ae07bb |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder